Mark L. Baum
Mr. Baum is a founder, board member and CEO of Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY). Beginning in 2011, Mr. Baum led the restructuring and reorganization of Imprimis,
including raising nearly $25M in new equity capital to support building Imprimis’ novel pharmaceutical innovation and distribution business. Prior to Mr. Baum’s involvement with Imprimis, from 2001 to 2011, he was the founder and managing director of California-based TBLF, LLC, where he managed a series of three funds, acting as a principal investor primarily in financing publicly traded companies or bridge-to-public-equity transactions. Before his fund management experience, in 1999, Mr. Baum founded and served as the president of YesRx, a publicly traded Los-Angeles-based closed-door pharmacy business. In 1998, after graduating from law school, Mr. Baum founded The Baum Law Firm, P.C. where he focused his practice on US securities laws, reporting requirements and public company finance-related issues that affect small capitalization public companies. Throughout his career, Mr. Baum has actively participated in numerous public company spin-offs, restructurings and recapitalizations, venture fundings, private-to-public mergers, asset acquisitions and divestitures. In addition to his experience financing, operating and advising small capitalization publicly-traded enterprises, Mr. Baum serves on the board of directors for Ideal Power, Inc. (NASDAQ: IPWR) where he is also chairman of the audit committee. Mr. Baum is also the chairman of the board of directors of Endra, Inc., a privately-held Ann Arbor, Michigan-based medical imaging company. Mr. Baum is a published inventor and is an inactive member of both the State Bar of California and the State Bar of Texas.
Andrew R. Boll
Mr. Boll has been the Chief Financial Officer of Imprimis Pharmaceuticals since February 2015. Mr. Boll oversees our accounting and financial reporting, investor relations, human resources and other operational departments.
From February 2012 to January 2015, he was our Vice-President of Accounting and Public Reporting and was a consultant to our Company from December 2011 up to his hire date. Mr. Boll has led the accounting and certain financial efforts related to the restructuring and reorganization of Imprimis, and has overseen our pharmacy acquisitions, and integration processes of those pharmacies.
Before joining Imprimis, from 2007 to 2011, Mr. Boll was an accountant for BCGU, LLC, a privately-held fund manager, and its related entities, that specialized in capital venture-type investment opportunities. While at BCGU, he provided CFO/Controller consulting services to public company clients, compiling numerous SEC financial reports, and participating in several public company restructurings, financings and private to public mergers. Mr. Boll previously held various accounting roles at Welsh Companies, LLC, a privately held commercial real estate company, its fund and its other subsidiaries (during 2004 to 2007). Mr. Boll is a CFA charterholder, Certified Management Accountant and earned his B.S. degree in Corporate and Public Finance. He is a member of the Institute of Management Accountants, the CFA Institute, and the CFA Society of San Diego.
Mr. Saharek is a senior healthcare industry executive with over 30 years of broad experience developing and commercializing pharmaceutical, biotech, surgical device and diagnostic product portfolios.
His results-oriented record of achievement includes designing and executing strategic commercial plans, building strong sustainable brands, launching new products, leading high performing teams and delivering outstanding results for a variety of healthcare companies. Over the past 15 years he has been focused in the ophthalmology segment where he has established valuable relationships with key opinion leaders and industry contacts.
Mr. Saharek has been our Chief Commercial Officer since February 2015. Prior to that he served as our Vice-President of Commercialization, Ophthalmology since November 2012. Before joining Imprimis, he served as Head of U.S. Marketing and Strategy for ThromboGenics Inc., developing the commercial strategy and building a team to launch a new biologic into the US market. Prior to that he was Vice President, Business Development at SurModics Inc., working with both large and small pharmaceutical companies on multi-platform drug delivery initiatives in the U.S. and internationally. Early on in his career he held positions of increasing responsibility in both marketing and sales at a number of companies, including his tenure with Bausch & Lomb. Mr. Saharek has a Masters of Business Administration from the University of Hartford and a Bachelor’s degree from Central Connecticut State University.
Mr. Seelhorst, has over 17 years of clinical and corporate development experience with both large-cap pharmaceutical companies (e.g. Eli Lilly and Pfizer) as well as start-up ventures including extensive capital raising, licensing, and M&A transactions.
Most recently, Gary has worked as a management consultant for several start-ups both raising capital and setting up strategic joint ventures in both the pharmaceutical and nanotechnology spaces. In 2012, he worked for HUYA Biosciences International in Global Business Development setting up both in-licensing and strategic partnerships primarily in China. From 2006 to 2011, he worked as VP of Business Development and Strategic Marketing for Naviscan, a medical device and biotech start-up wherein he helped to build up both the commercial side of the business as well as execute many in- and out-licensing deals which lead to some significant partnerships with Fortune 500 companies, i.e. Johnson & Johnson, Hologic, and CR Bard. From 1998 to 2006, Gary worked at Pfizer in various positions in Clinical Development as well as Corporate Development, helping to initiate a burgeoning in-licensing and M&A campaign which resulted in several large M&A transactions. From 1996 to 1998, Gary worked as a Medical Writer for Eli Lilly with his entire tenure devoted to writing a successfully approved NDA for Prozac®. Gary received an MBA from the University of Michigan, an MS from Indiana University, and a Bachelor’s degree from the University of California at San Diego.
Mr. Bitterman is an experienced pharmacy operations leader with a 30-year track record of acquiring, building and maintain high performing pharmacies. Mr. Bitterman joins us most recently from UCSD Health Systems where he was the Pharmacy Manager of Perlman Medical Center.
While at UC San Diego Health System, he oversaw the UCSD mail order operations and created the Thornton Discharge Pharmacy and was a volunteer faculty member of USCD Skagg’s School of Pharmacy. He presented lectures to pharmacy school students on such topics as emergency contraception, HIPAA, and “Real World Pharmacy Issues.” Mr. Bitterman has also participated in several California State Board of Pharmacy sponsored programs and Health Fairs. From 1982 to 2009, Mr. Bitterman was a Pharmacy Area Supervisor and Pharmacy District Manager and held various other positions at Long’s Drugs, which was acquired by CVS. He was involved with acquisitions of independent pharmacies, file buys, training and mentoring pharmacy managers and recruiting of pharmacists. Mr. Bitterman is Six Sigma trained and has been a trainer for HIPPA, new pharmacy managers, pharmacy technicians and has supervised up to 38 retail pharmacies. He received a Bachelor’s degree in Pharmacy from the St. John’s University in New York, and is a licensed Pharmacist in New York and California.
Victor Repkin, Ph.D., has served as patent attorney and intellectual property analyst for Imprimis Pharmaceuticals since June 2013. Dr. Repkin has more than 15 years of experience in patent preparation and prosecution, patent counseling and due diligence.
He has extensive experience drafting and prosecuting patents in synthetic organic chemistry, polymer chemistry, pharmaceuticals, and protein and enzyme technologies. Dr. Repkin has drafted or prosecuted over 170 issued patents and hundreds more pending patent applications, and has coordinated prosecution and enforcement in the US and worldwide for therapeutics developed by pharmaceutical, biotechnology and medical device companies. In addition, Dr. Repkin has an extensive background as a research chemist. From 1985 through 1993, he held a variety of research positions, including senior research chemist, with E.I. DuPont de Nemours and Co., Wacker Silicones Corp. and Pigment Co. Dr. Repkin received his B.S. and M.S. in Chemistry and Chemical Engineering and his Ph.D. in Polymer and Organic Chemistry from Leningrad Institute of Technology and his J.D. from Thomas Jefferson School of Law.